Surrozen, Inc. (SRZN) NASDAQ
23.15
-1.565(-6.33%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
23.15
-1.565(-6.33%)
Currency In USD
| Previous Close | 24.71 |
| Open | 24.71 |
| Day High | 24.91 |
| Day Low | 22.71 |
| 52-Week High | 35 |
| 52-Week Low | 8 |
| Volume | 122,454 |
| Average Volume | 107,531 |
| Market Cap | 173.06M |
| PE | -0.63 |
| EPS | -36.59 |
| Moving Average 50 Days | 28.88 |
| Moving Average 200 Days | 20.64 |
| Change | -1.57 |
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 12, 2025 10:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe e
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Sep 04, 2025 8:15 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe
Surrozen to Present at Upcoming Healthcare Investor Conference
GlobeNewswire Inc.
Aug 06, 2025 8:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and reg